US 10449191
Treatment of prostate cancer
granted A61KA61K31/4166A61K31/501
Quick answer
US patent 10449191 (Treatment of prostate cancer) held by Takeda Pharmaceutical Company Limited expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/4166, A61K31/501, A61K31/513, A61K31/519